logo-loader
viewInstem PLC

Instem chosen for US$1mln contract by top South Korean research group

"We have remained very busy, have good visibility over a strong H1 2020 performance and continue to have confidence in the longer-term outlook"

Instem PLC -
We continue to have a strong footprint in the Asia-Pacific region"

Instem PLC (LON:INS) said it has won a contract worth to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea.

The contract is worth approximately US$1mln, the group said in a statement, with a majority of the revenue to be recognised in 2020 and the balance in 2021.

Instem said it will provide the Korean company with a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions. These will help it to automate and optimize stud- related processes at Biotoxtech's facility in North Chungcheong Province, it added.

Instem said it was awarded the contract after a competitive tender, which recognised its leading position in non-clinical IT solutions.

Biotoxtech has already received certifications for Good Laboratory Practices by international regulators, including the US Food & Drug Administration.

Phil Reason, Instem’s chief executive, said he was delighted with the contract.

“South Korea has been investing heavily in its pharmaceutical R&D capabilities and has become a significant player on the global stage. We continue to have a strong footprint in the Asia-Pacific region and are working hard to ensure that we maintain our world-leading market position," he added.

CEP says it is very busy in spite of coronavirus disruption

Instem also revealed results for the year to end December 2019, which saw revenues increase 13% to £25.7mln and underlying profits (adjusted EBITDA) rise to £4.9mln from £4.1mln.

Recurring revenue rose 9% to £14.9mln, while software-as-a service (SaaS) sales improved £16mln to £6.4mln.

After goodwill and intangible asset impairments, Instem recorded a loss of £900,000 (£1.7mln profit).

Reason said there has been some uncertainty due to the coronavirus (COVID-19) outbreak, but added most of its revenue comes from clients with laboratories that are regarded as essential businesses and many are working on COVID-19 related vaccines and therapies. 

“Consequently, we have remained very busy, have good visibility over a strong H1 2020 performance and continue to have confidence in the longer-term outlook for the business, supported by a strong cash balance at the end of April 2020 of £8.3mln,” he added.

Quick facts: Instem PLC

Price: 454 GBX

AIM:INS
Market: AIM
Market Cap: £75.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem PLC's Phil Reason says they've been really busy during lockdown and...

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy'...

on 4/6/20

2 min read